Eli Lilly to Acquire Kelonia Therapeutics in Deal Valued Up to $7 Billion

Eli Lilly to Acquire Kelonia Therapeutics in Deal Valued Up to $7 Billion
1 min readBusinessHealthTechnology

In Brief

The acquisition aims to expand Eli Lilly's capabilities in developing in vivo CAR-T cell therapies for cancer treatment.

Key Facts

  • Eli Lilly has agreed to acquire Kelonia Therapeutics, a cancer drug maker, in a deal worth up to $7 billion.
  • Kelonia is developing technology to reprogram patients' T-cells inside the body, known as in vivo CAR-T.
  • The deal is intended to advance Eli Lilly's position in the field of in vivo CAR-T cell therapies.
  • The acquisition was reported by multiple outlets, including CNBC and Google News.
  • The transaction reflects ongoing interest in cell therapy technologies within the pharmaceutical industry.

What Happened

Eli Lilly announced an agreement to acquire Kelonia Therapeutics, a company focused on in vivo CAR-T cell therapy technology, in a deal valued at up to $7 billion.

Why It Matters

This acquisition could enhance Eli Lilly's research and development in cancer immunotherapy, potentially leading to new treatment options for patients using in vivo CAR-T technology.

What's Next

Observers will watch for regulatory approval of the deal and for updates on the progress of Kelonia's in vivo CAR-T programs under Eli Lilly's ownership.

Sources